Is AOD-9604 Legal in Virginia?

Understanding the Federal Framework First

AOD-9604 is not a scheduled controlled substance under the Controlled Substances Act, but that fact alone does not make it freely legal to prescribe or dispense. The relevant federal law governing access is the Drug Quality and Security Act of 2013 (DQSA), which created two categories of compounding pharmacy: 503A (traditional patient-specific compounding) and 503B (outsourcing facilities producing larger batches). Both categories operate under FDA oversight, and the FDA publishes specific lists of bulk drug substances that compounders may or may not use. AOD-9604's position on those lists is the controlling issue for Virginia patients and prescribers.

What the DQSA Actually Says

The DQSA amended the Federal Food, Drug, and Cosmetic Act to permit compounding only when the bulk substances used are either on a positive ("Category 1") list of substances nominated and evaluated by the FDA, or have not yet been evaluated (a temporary gray zone). Substances placed on the "Category 2" list have been evaluated and found to present safety or clinical-evidence concerns that prevent their authorization for compounding. This is not the same as a DEA schedule. It is an FDA determination about whether a substance meets the evidentiary bar to be compounded without an approved New Drug Application (NDA). The full statutory text of DQSA Section 503A is available through the FDA's website.

AOD-9604's Specific Position on the FDA Bulk Substances List

The FDA has placed AOD-9604 on the list of bulk drug substances that are not eligible for use in 503A compounding. The agency's evaluation concluded that AOD-9604 lacks adequate clinical evidence to support its use in compounded preparations, and that its inclusion in traditional compounding would present potential risks without demonstrated benefit. The FDA's final guidance on bulk substances for 503A compounding is published and searchable on the FDA website.

This single federal determination is why Virginia patients cannot simply walk into a local compounding pharmacy with a prescription for AOD-9604. The pharmacy would be violating federal law by filling it, regardless of what Virginia state law says or does not say.

Virginia State Law: What the Commonwealth Actually Regulates

Virginia has its own pharmacy practice act, codified in the Code of Virginia Title 54.1, Chapter 33, which the Virginia Board of Pharmacy administers. The Board sets standards for compounding, licensing, and dispensing within the state. Critically, Virginia's regulatory framework incorporates federal compounding standards by reference and does not create an independent carve-out that permits substances the FDA has restricted. The Virginia Board of Pharmacy's compounding guidance aligns with USP <795> and <797> standards, which are themselves referenced in FDA compliance policy guides.

No Virginia-Specific Ban, But No Virginia-Specific Permission

Virginia has not passed legislation that specifically names AOD-9604. The peptide does not appear in Virginia's Schedule I through VI controlled substance lists, which means it is not a state-controlled substance. That is an accurate statement. It does not mean the peptide is freely obtainable or prescribable in the state. Legality in the pharmaceutical context is determined by both what is prohibited and what is affirmatively authorized. AOD-9604 has no affirmative authorization as a prescription drug or compounded preparation in Virginia or anywhere else in the United States.

How the Virginia Board of Pharmacy Enforces Federal Rules

The Virginia Board of Pharmacy has authority under Va. Code § 54.1-3307 to discipline pharmacists and pharmacies for violations of federal pharmacy law, including the FDCA. A Virginia-licensed pharmacy that compounds AOD-9604 for human use is simultaneously violating federal law and exposing its Virginia license to disciplinary action. This dual enforcement mechanism is why the FDA's Category 2 determination has direct, immediate practical consequences in Virginia even without a separate state statute. Pharmacists in Virginia are trained to cross-check the FDA's bulk substance lists before compounding any peptide product.

The 503B Outsourcing Facility Route: Also Blocked

Some patients ask whether a 503B outsourcing facility, which can produce non-patient-specific batches, could supply AOD-9604. The answer is no. The FDA's restrictions on AOD-9604 apply to 503B facilities as well. Section 503B of the FDCA requires that bulk drug substances used by outsourcing facilities either appear on an FDA-approved list or meet specific conditions tied to clinical need and shortage status. AOD-9604 appears on neither the approved list nor a current drug shortage list. FDA guidance on 503B outsourcing facility requirements is publicly available, and the agency has consistently enforced these restrictions through warning letters to facilities that compound peptides outside the permitted lists.

The FDA issued multiple warning letters between 2020 and 2023 targeting compounding pharmacies and outsourcing facilities that supplied unapproved peptides, including BPC-157, TB-500, and similar compounds. AOD-9604 falls into the same regulatory category.

What AOD-9604 Actually Is: The Science Behind the Legal Questions

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177 to 191 of human growth hormone (hGH). It was originally developed by Metabolic Pharmaceuticals in Australia and investigated under the trade name Tenovate for obesity treatment. The compound showed early promise in rodent models for lipolysis and fat metabolism without the insulin-desensitizing effects associated with full-length hGH.

Clinical Trial History

Two Phase 2 trials in humans produced modest or null results on the primary endpoint of weight loss. A 12-week placebo-controlled trial (N=300) published data showing that oral AOD-9604 at doses of 1 mg daily did not produce statistically significant weight reduction compared to placebo. Metabolic Pharmaceuticals subsequently abandoned the obesity indication. The compound never reached Phase 3 development for obesity. ClinicalTrials.gov records for AOD-9604 studies show no currently active interventional human trials in the United States.

FDA GRAS Designation: What It Does and Does Not Mean

AOD-9604 received FDA Generally Recognized as Safe (GRAS) status as a food ingredient in 2014, specifically for use in functional foods. This designation is frequently misunderstood online. GRAS status for a food ingredient does not grant approval for use as a drug or as a bulk compounding substance. The legal standard for GRAS is entirely separate from the New Drug Application process. The FDA's own guidance explicitly states that a food ingredient's GRAS status has no bearing on its regulatory status as a pharmaceutical agent. The FDA's GRAS database confirms AOD-9604 was submitted as GRN 000612, covering use as a food ingredient only.

Clinicians who have encountered marketing materials claiming AOD-9604 is "FDA-approved" or "FDA-safe for clinical use" based on the GRAS designation are reading a selective and misleading interpretation of the regulatory record.

Gray-Market and Research-Use Channels: The Real Risk Picture

Several online vendors sell AOD-9604 labeled "for research use only" or "not for human consumption." These products are not regulated by the FDA for purity, sterility, potency, or identity. Independent laboratory analyses of peptides purchased from gray-market research chemical suppliers have detected significant variability in actual peptide concentration, the presence of contaminants including heavy metals, and in some cases misidentified compounds entirely.

Purchasing AOD-9604 from an unregulated online source and self-administering it involves three distinct legal and safety risks. First, the product has no guaranteed sterility or potency, making subcutaneous injection particularly dangerous. Second, the purchaser has no legal protection if the product causes harm, since no FDA-regulated dispensing occurred. Third, although personal possession of AOD-9604 is not a criminal offense under federal or Virginia law (it is not a controlled substance), a licensed clinician who recommends or supplies a gray-market peptide to a patient is violating their professional obligations and could face board action.

What "Research Use Only" Actually Means Legally

The "research use only" label on a compound signals that the vendor is selling to licensed research institutions for in-vitro or animal research, not for human clinical use. It does not create a legal pathway for a Virginia physician to prescribe it or for a Virginia resident to self-inject it as a medical treatment. The FDA's policy on research chemicals sold for human use is unambiguous: marketing a substance as a drug for human use without an approved NDA is a violation of the FDCA regardless of how the label is worded.

How Virginia Prescribers Manage Peptide Therapy Legally

Virginia physicians, nurse practitioners, and physician assistants can legally prescribe peptides that are either FDA-approved drugs or are on the FDA's positive list for 503A or 503B compounding. Several peptides do fall into legal compounding territory. Sermorelin, for example, was previously FDA-approved and has been compounded legally, though it has faced its own regulatory changes. Ipamorelin and CJC-1295 have been the subject of ongoing FDA review. Tesamorelin (Egrifta) carries an approved NDA for HIV-associated lipodystrophy.

What a Compliant Prescription Pathway Looks Like

A compliant peptide prescription in Virginia involves a licensed Virginia prescriber who: conducts a good-faith patient evaluation (in-person or via telehealth meeting Virginia's telehealth standards under Va. Code § 54.1-2952.1); documents a clinical indication; writes a prescription for a compound on the FDA's permitted bulk substance list; and directs the prescription to a 503A pharmacy that is licensed in Virginia or a 503B outsourcing facility shipping legally into Virginia. AOD-9604 does not fit this pathway at any step because it is on the prohibited list before the prescription is even written.

The Telehealth Angle

Virginia's telehealth laws, updated significantly after 2020, permit prescribers to establish care and prescribe via synchronous video consultation. This does not change the federal compounding rules. A telehealth company operating out of Florida, Texas, or any other state that offers AOD-9604 prescriptions to Virginia residents is operating outside federal compounding law regardless of which state it is incorporated in. The FDA's jurisdiction covers the drug product, not just the prescriber's location.

What Might Change: Regulatory Pathways Worth Watching

The FDA's bulk substance review process is ongoing. A nominator (typically a compounding pharmacy trade organization, a physician organization, or a manufacturer) can submit a nomination for reconsideration of any substance on the Category 2 list. For AOD-9604 to re-enter legal compounding, a nominator would need to submit new clinical data demonstrating safety and efficacy in a specific compounded indication, and the FDA's Pharmacy Compounding Advisory Committee (PCAC) would need to recommend approval.

As of the date of this article's publication, no active nomination for AOD-9604 reconsideration appears in the FDA's publicly available PCAC meeting records. PCAC meeting materials and agendas are posted on the FDA's advisory committee page.

If new human trial data were generated, particularly data showing a clinically meaningful weight loss effect with a well-characterized safety profile, the legal field could shift. The original Phase 2 data was not sufficient to cross that bar. A properly powered Phase 3 trial with a primary endpoint meeting FDA standards for drug approval would be the clearest path.

Practical Guidance for Virginia Patients Seeking Peptide-Based Weight Management

Patients asking about AOD-9604 in Virginia are typically interested in its proposed mechanism: preferential lipolysis with reduced anabolic side effects compared to full hGH. That is a legitimate clinical interest. There are FDA-compliant options worth discussing with a qualified prescriber.

Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). The full STEP-1 results are published in the New England Journal of Medicine. This is a dramatically larger clinical effect than anything demonstrated for AOD-9604 in human trials.

Tirzepatide 15 mg (Zepbound) showed mean weight loss of 20.9% at 72 weeks in the SURMOUNT-1 trial (N=2,539) versus 3.1% with placebo. SURMOUNT-1 results appear in the New England Journal of Medicine. Both agents are available to Virginia patients through compliant prescribing pathways, including telehealth.

For patients who prefer a peptide mechanism and are specifically interested in growth hormone secretagogues, sermorelin's legal compounding status has historically been more favorable than AOD-9604's, though prescribers should verify the current FDA bulk substance status before writing a prescription given ongoing regulatory revisions.

The American Association of Clinical Endocrinology (AACE) 2023 Obesity Guidelines recommend a stepwise approach to weight management that prioritizes FDA-approved pharmacotherapy before off-label or investigational agents. The AACE clinical practice guidelines specifically advise clinicians to use agents with demonstrated efficacy in randomized controlled trials. AOD-9604 does not meet that standard based on available human data.